Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics (NASDAQ: MYGN) has announced a partnership with INTERLINK Care Management's CancerCARE for Life to expand access to hereditary cancer testing. The agreement will enable over one million CancerCARE network members to assess their eligibility for the MyRisk test through the MyGeneHistory quiz.
The MyRisk with RiskScore Hereditary Cancer Test evaluates 48 genes associated with hereditary cancer risk across 11 different cancers. The test combines family history and clinical factors like breast density to provide patients with a five-year and lifetime breast cancer risk assessment. Eligible patients who meet the criteria can be connected with clinicians to order the test and review results with Myriad genetic counselors.
Myriad Genetics (NASDAQ: MYGN) ha annunciato una partnership con il CancerCARE for Life di INTERLINK Care Management per ampliare l'accesso ai test genetici per il cancro ereditario. L'accordo permetterà a oltre un milione di membri della rete CancerCARE di valutare la loro idoneità per il test MyRisk attraverso il quiz MyGeneHistory.
Il test MyRisk con RiskScore per il cancro ereditario valuta 48 geni associati al rischio di cancro ereditario in 11 diversi tipi di cancro. Il test combina la storia familiare e fattori clinici come la densità mammaria per fornire ai pazienti una valutazione del rischio di cancro al seno a cinque anni e nella vita. I pazienti idonei che soddisfano i criteri possono essere messi in contatto con i clinici per ordinare il test e rivedere i risultati con i consulenti genetici di Myriad.
Myriad Genetics (NASDAQ: MYGN) ha anunciado una asociación con el CancerCARE for Life de INTERLINK Care Management para expandir el acceso a pruebas genéticas de cáncer hereditario. El acuerdo permitirá que más de un millón de miembros de la red CancerCARE evalúen su elegibilidad para la prueba MyRisk a través del cuestionario MyGeneHistory.
La prueba MyRisk con RiskScore para el cáncer hereditario evalúa 48 genes asociados con el riesgo de cáncer hereditario en 11 tipos diferentes de cáncer. La prueba combina la historia familiar y factores clínicos como la densidad mamaria para proporcionar a los pacientes una evaluación del riesgo de cáncer de mama a cinco años y a lo largo de su vida. Los pacientes elegibles que cumplen con los criterios pueden ser conectados con clínicos para solicitar la prueba y revisar los resultados con los consejeros genéticos de Myriad.
Myriad Genetics (NASDAQ: MYGN)는 유전성 암 검사에 대한 접근성을 확장하기 위해 INTERLINK Care Management의 CancerCARE for Life와 파트너십을 발표했습니다. 이 계약은 100만 명 이상의 CancerCARE 네트워크 회원들이 MyGeneHistory 퀴즈를 통해 MyRisk 검사의 적격성을 평가할 수 있도록 합니다.
RiskScore를 포함한 MyRisk 유전성 암 검사는 11종의 다양한 암과 관련된 48개의 유전자를 평가합니다. 이 검사는 가족력을 비롯한 임상적 요인을 결합하여 환자에게 5년 및 평생 유방암 위험 평가를 제공합니다. 기준을 충족하는 적격 환자는 의사와 연결되어 검사를 의뢰하고 Myriad의 유전자 상담사와 결과를 검토할 수 있습니다.
Myriad Genetics (NASDAQ: MYGN) a annoncé un partenariat avec CancerCARE for Life d'INTERLINK Care Management afin d'élargir l'accès aux tests génétiques héréditaires pour le cancer. Cet accord permettra à plus d'un million de membres du réseau CancerCARE d'évaluer leur éligibilité pour le test MyRisk via le quiz MyGeneHistory.
Le test MyRisk avec RiskScore pour le cancer héréditaire évalue 48 gènes associés au risque de cancer héréditaire sur 11 types de cancer différents. Le test combine les antécédents familiaux et des facteurs cliniques tels que la densité mammaire pour fournir aux patients une évaluation du risque de cancer du sein sur cinq ans et à vie. Les patients éligibles répondant aux critères peuvent être mis en contact avec des cliniciens pour commander le test et examiner les résultats avec les conseillers génétiques de Myriad.
Myriad Genetics (NASDAQ: MYGN) hat eine Partnerschaft mit dem CancerCARE for Life von INTERLINK Care Management angekündigt, um den Zugang zu erblichen Gentests auf Krebs zu erweitern. Die Vereinbarung ermöglicht es über einer Million Mitglieder des CancerCARE Netzwerks, ihre Berechtigung für den MyRisk-Test über das MyGeneHistory-Quiz zu bewerten.
Der MyRisk-Test mit RiskScore für erblichen Krebs bewertet 48 Gene, die mit dem Risiko für erblich bedingten Krebs bei 11 verschiedenen Krebsarten in Verbindung stehen. Der Test kombiniert die Familiengeschichte und klinische Faktoren wie die Brustdichte, um den Patienten eine fünfjährige und lebenslange Risikobewertung für Brustkrebs zu geben. Berechtigte Patienten, die die Kriterien erfüllen, können mit Klinikern verbunden werden, um den Test zu bestellen und die Ergebnisse mit den genetischen Beratern von Myriad zu besprechen.
- Access to MyRisk test expanded to over 1 million potential new customers through CancerCARE network
- Strategic partnership enhances market reach and distribution channels
- None.
Insights
This strategic partnership marks a significant commercial expansion for Myriad Genetics, potentially driving substantial revenue growth through access to CancerCARE's network of over 1 million members. The agreement's structure is particularly noteworthy for three key reasons:
First, the integration of MyGeneHistory as a pre-screening tool creates an efficient patient funnel, potentially increasing test conversion rates while minimizing unnecessary testing costs. This approach aligns with value-based care principles, optimizing healthcare resource utilization.
Second, MyRisk's comprehensive coverage of 48 genes and 11 cancer types, combined with its unique RiskScore feature for all ancestries, provides Myriad with a strong competitive advantage in the growing genetic testing market. The inclusion of polygenic risk assessment differentiates the offering from standard genetic panels.
Third, the partnership's emphasis on genetic counseling support addresses a critical healthcare delivery challenge, potentially increasing test adoption rates and patient satisfaction while reducing liability risks. This comprehensive approach could serve as a model for future genetic testing partnerships.
The deal's structure suggests a focus on sustainable growth rather than just volume, with potential for recurring revenue through family member testing and longitudinal risk assessment. For investors, this represents a strategic positioning in the preventive cancer care market, which is increasingly important as healthcare systems shift toward early detection and prevention models.
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members.
The agreement enables more than one million individuals within CancerCARE’s network to assess their eligibility for the MyRisk test by taking the MyGeneHistory® quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the MyRisk® with RiskScore® Hereditary Cancer Test on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor.
“MyRisk’s clear, actionable results provide the foundation for personalized care plans, empowering patients to make confident, informed decisions about their medical management,” said Melissa Gonzales, President, Women’s Health, Myriad Genetics. “Expanding access through CancerCARE’s network will give more patients the opportunity to take the MyRisk with RiskScore Hereditary Cancer Test.”
MyRisk with RiskScore is the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. MyRisk evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with an individualized five-year and remaining lifetime breast cancer risk assessment.
“Working with Myriad Genetics is extremely important, and we look forward to enhancing our relationship over time. We share a common goal of educating and enabling consumers to access early genetic screening to support personal and family health,” said Oscar Bronsther, MD, Chief Medical Officer at CancerCARE for Life. “We are excited to provide our members with access to the MyRisk Hereditary Cancer Test, which can help identify patients who may be at increased risk of developing cancer.”
Myriad’s Breast Cancer Risk Assessment Program features the MyRisk with RiskScore Hereditary Cancer Test, the first and industry-leading hereditary cancer test and polygenic breast cancer risk assessment for all ancestries. It includes MyGeneHistory, an online screening tool that helps assess if a patient meets medical guidelines for hereditary cancer testing. The program also includes patient education about genetic testing and a guide on how to collect family history of certain cancers. For more information, please visit Myriad.com/seemore.
About CancerCARE
CancerCARE and CancerCARE for Life comprise one of the nation’s largest prevention, early detection and cancer management programs. CancerCARE for Life’s unique approach blends targeted education and awareness with personalized oncology trained nurses and physicians to deliver an exceptional member experience. Expertise in clinical trials, Center of Excellence (COE) access, pre-guideline care, NCCN1 Guideline® care, and gene and cellular therapy help ensure the best outcomes for members.
About Myriad Genetics
Myriad Genetics is a leading genetic and genomic tumor testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s collaboration with CancerCARE for Life and its potential to expand patient access to the MyRisk with RiskScore Hereditary Cancer Test, empowering patients to make confident, informed decisions about their medical management. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
1 National Comprehensive Cancer Network (NCCN) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
FAQ
What is the impact of MYGN's partnership with CancerCARE for Life on market reach?
How many genes does MYGN's MyRisk with RiskScore test evaluate?
What services are included in MYGN's Breast Cancer Risk Assessment Program?
How do CancerCARE members access MYGN's MyRisk testing service?
